{"id":"W4379284114","doi":"10.1200/jco.2023.41.16_suppl.tps1123","title":"INAVO121: Phase III study of inavolisib (INAVO) + fulvestrant (FUL) vs. alpelisib (ALP) + FUL in patients (pts) with hormone receptor-positive, HER2-negative (HR+, HER2–) <i>PIK3CA</i>-mutated (mut) locally advanced or metastatic breast cancer (LA/mBC).","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"ca_institutions":"Roche (Canada)","funders":"Roche","keywords":"Medicine; Fulvestrant; Tolerability; Regimen; Internal medicine; Everolimus; Oncology; Pharmacology; Cancer; Adverse effect; Breast cancer; Estrogen receptor","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001243687,0.001450944,0.002120866,0.0004447972,0.0003560272,0.00208313,0.001520619,0.001620322,0.006513752],"category_scores_gemma":[0.0009536544,0.0007381978,0.001999709,0.0004608341,0.0008963045,0.001026041,0.0004558501,0.004365788,0.002264156],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0009592679,"about_ca_system_score_gemma":0.001620202,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001107311,"about_ca_topic_score_gemma":0.002941418,"domain_scores_codex":[0.9997098,0.0001040281,0.00001225044,0.00005651069,0.00003309431,0.00008429678],"domain_scores_gemma":[0.9994171,0.0000778029,0.0001008848,0.00005137957,0.00003925884,0.0003135813],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.7190613,0.0772398,0.003511324,0.00174648,0.001948529,0.0001768144,0.0003112966,0.004456038,0.04265653,0.001012504,0.01126732,0.1366121],"study_design_scores_gemma":[0.6345703,0.3439625,0.006447132,0.000138427,0.0007630603,0.0003716924,0.0001206702,0.002165119,0.003762541,0.0006290233,0.007008,0.0000615557],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9710733,0.008635166,0.001588417,0.001086755,0.000767279,0.004615836,0.003616008,0.0004733411,0.008143928],"genre_scores_gemma":[0.9679612,0.006000221,0.001947533,0.002176383,0.0003780328,0.004094376,0.008287123,0.0001341949,0.009020904],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.006513752,"threshold_uncertainty_score":0.02179062,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04563171507472753,"score_gpt":0.4278713048804936,"score_spread":0.3822395898057661,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}